Dataset Information

Long-term safety and efficacy of nalmefene in Japanese patients with alcohol dependence.

ABSTRACT: AIM:The safety and efficacy of nalmefene in Japanese patients with high or very high World Health Organization drinking risk level of alcohol dependence were assessed in a multicenter, randomized, double-blind, placebo-controlled, phase 3 (lead-in) study. Here, the long-term safety and efficacy of nalmefene in an open-label extension of the lead-in study are presented. METHODS:Patients who completed the 24-week lead-in study were eligible for the extension study, where they were treated with nalmefene 20?mg as needed for 24?weeks. The long-term safety and efficacy of nalmefene 20?mg during the total 48-week period were evaluated. Treatment-emergent adverse events during the study period were recorded and change from baseline in the number of heavy drinking days and total alcohol consumption were calculated. RESULTS:Overall, long-term nalmefene 20?mg was well tolerated; the main treatment-emergent adverse events reported in ?5% of patients included nasopharyngitis (37.2%), nausea (36.5%), somnolence (21.2%), dizziness (16.8%), malaise (14.6%), and vomiting (12.4%). The number of heavy drinking days and total alcohol consumption decreased from baseline to 48?weeks (mixed model for repeated measures, least squares mean?±?standard error, -15.09?±?0.77?days/month and?-53.20?±?2.29 g/day, respectively) during the study. CONCLUSION:This long-term evaluation in Japanese patients with high or very high drinking risk levels of alcohol dependence indicated that nalmefene was safe, well tolerated, and efficacious.

SUBMITTER: Higuchi S

PROVIDER: S-EPMC7496902 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Long-term safety and efficacy of nalmefene in Japanese patients with alcohol dependence.

Higuchi Susumu S Takahashi Masayoshi M Murai Yoshiyuki Y Tsuneyoshi Kana K Nakamura Izuru I Meulien Didier D Miyata Hisatsugu H

Psychiatry and clinical neurosciences 20200527 8

<h4>Aim</h4>The safety and efficacy of nalmefene in Japanese patients with high or very high World Health Organization drinking risk level of alcohol dependence were assessed in a multicenter, randomized, double-blind, placebo-controlled, phase 3 (lead-in) study. Here, the long-term safety and efficacy of nalmefene in an open-label extension of the lead-in study are presented.<h4>Methods</h4>Patients who completed the 24-week lead-in study were eligible for the extension study, where they were t ...[more]

PMID: 32359104

Similar Datasets

Project description:ObjectiveTo assess long-term (up to 2 years) efficacy, tolerability, and safety of erenumab for the prevention of episodic migraine (EM) in Japanese patients.BackgroundPreviously published results from the double-blind treatment phase (DBTP) of a phase 2 clinical study have demonstrated the efficacy and safety of erenumab in Japanese patients with EM.MethodsPatients completing the 24-week placebo-controlled DBTP could continue into the 76-week open-label treatment phase (OLTP), receiving erenumab 70 mg or 140 mg subcutaneously once monthly. The initial dose in the OLTP was erenumab 70 mg monthly, which was later changed to 140 mg. After study completion, the following were assessed: change from baseline in monthly migraine days (MMD), change from baseline in monthly acute migraine-specific medication days (MSMD), percentage of patients achieving ≥50% and ≥75% reduction in MMD, change from baseline in the 6-item Headache Impact Test (HIT-6™) score, and safety (exposure-adjusted patient-incidence of adverse events [AEs], calculated as number of patients per 100 patient-years).ResultsOf 475 patients enrolled in the DBTP, 459 (96.6%) continued in the OLTP. The mean (SD) MMD was 7.9 (2.3) at baseline with the overall change from baseline at week 100 of -2.9 (4.1) days. The monthly acute MSMD was 5.7 (2.8) at baseline with change from baseline at week 100 of -1.7 (3.7) days. The proportion of patients who achieved ≥50% and ≥75% reduction in MMD from baseline at week 100 was 177/398 (44.5%) and 94/398 (23.6%), respectively. The HIT-6™ score was 58.4 (5.4) at baseline with a change of -6.4 (8.2) at week 100. The exposure-adjusted patient-incidence of AEs during the OLTP was 207.1/100 patient-years for the combined erenumab group, similar to that observed for either erenumab (271.0/100 patient-years) or placebo (257.3/100 patient-years) during the DBTP, and no new safety signals were detected during the OLTP.ConclusionLong-term erenumab treatment in Japanese patients with EM demonstrated sustained efficacy for up to 2 years, with a safety profile similar to previous studies, supporting erenumab as a potential new therapy for EM prevention in Japan.

Dataset Information

Long-term safety and efficacy of nalmefene in Japanese patients with alcohol dependence.

Publications

Long-term safety and efficacy of nalmefene in Japanese patients with alcohol dependence.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets